What is Constructive Bio?
Constructive Bio is a pioneering force in the field of synthetic biology, specializing in the design and construction of entirely synthetic genomes. By reprogramming the genetic code of living organisms, the company enables the synthesis of programmable polymers, effectively transforming biological cells into sustainable bio-factories. This platform technology has already yielded virus-resistant organisms, demonstrating the practical utility of their genetic engineering approach. As the industry moves toward more sustainable production methods, Constructive Bio provides the foundational tools necessary to realize the next generation of bio-based materials and advanced medical therapies, positioning itself at the intersection of deep science and industrial application.
How much funding has Constructive Bio raised?
Constructive Bio has raised a total of $73M across 2 funding rounds:
Angel/Seed
$15M
Series A
$58M
Angel/Seed (2022): $15M, investors not publicly disclosed
Series A (2024): $58M led by Paladin Capital Group, Omx Ventures, Fine Structure Ventures, NanoDimension, and Ahren Innovation Capital
Key Investors in Constructive Bio
Paladin Capital Group
A global multi-stage investment firm specializing in venture capital and growth financing, providing strategic guidance and operational support to scale companies across diverse sectors.
Omx Ventures
A biotechnology-focused investment firm that utilizes a technology-first approach to support companies leveraging data, bio-tools, and artificial intelligence to revolutionize medicine.
Fine Structure Ventures
A venture capital firm dedicated to commercializing disruptive scientific and technological innovations, offering board representation and guidance from early-stage through pre-IPO.
What's next for Constructive Bio?
Looking ahead, the strategic deployment of the $58M will likely focus on scaling the company's bio-manufacturing infrastructure and expanding its intellectual property portfolio. With the support of its diverse investor base, Constructive Bio is expected to transition from a research-heavy entity to a commercial-stage enterprise. Key priorities will include the optimization of its genetic reprogramming platform for broader industrial applications and the pursuit of strategic partnerships to integrate its bio-factory technology into existing supply chains. As the firm continues to mature, the focus will remain on maintaining its competitive edge in genome engineering while navigating the regulatory and technical complexities inherent in the synthetic biology market.
See full Constructive Bio company page
